This phase I/II study is evaluating how safe and effective a new targeted therapy (SAR443579) is in people with relapsed or refractory acute myeloid leukaemia, B-cell acute lymphoblastic leukaemia, or high-risk myelodysplasia.
This trial is treating patients with acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplasia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS)
This trial has dose escalation and dose expansion stages. In the dose escalation stage, participants will receive SAR443579 intravenously at escalating dose levels. In the dose expansion stage, participants will receive SAR443579 intravenously at the recommended dose and schedule determined in the dose escalation stage.
Recruiting Hospitals Read More